Company intelligence / Profile preview
GeneSail Biotech
Shanghai, Shanghai Shi, Chinagenesailbiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GeneSail Biotech’s leading program involves an oncolytic vaccinia virus engineered to express both anti-PD‑1 and anti‑4‑1BB antibodies for cancer-targeted immunotherapy. The most advanced asset has reached IND approval; another related program remains in preclinical development. No clinical results have been published as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyMonoclonal antibodyOncolytic virus therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on GeneSail Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneSail Biotech.